Propanc Biopharma, Inc. (OTCMKTS:PPCB – Get Free Report)’s stock price fell 15.9% during trading on Wednesday . The company traded as low as $5.68 and last traded at $5.68. 432 shares changed hands during trading, an increase of 2% from the average session volume of 425 shares. The stock had previously closed at $6.75.
Propanc Biopharma Price Performance
The firm’s 50-day simple moving average is $6.43 and its two-hundred day simple moving average is $2.25.
Propanc Biopharma Company Profile
Propanc Biopharma, Inc, a biopharmaceutical company, develops cancer treatments for patients with pancreatic, ovarian, and colorectal cancer in Australia. It offers PRP, a formulation lead product that is in preclinical phase of development designed to enhance the anti-cancer effects of multiple enzymes.
Featured Articles
- Five stocks we like better than Propanc Biopharma
- What is a Low P/E Ratio and What Does it Tell Investors?
- Energy Transfer: Powering Data With Dividends and Diversification
- What is the Euro STOXX 50 Index?
- Qualcomm Stock Is Coiling for a Breakout
- EV Stocks and How to Profit from Them
- Is Alphabet Too Cheap to Ignore After Its Recent Correction?
Receive News & Ratings for Propanc Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Propanc Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
